Dennis G Moledina1,2, Randy L Luciano1, Lidiya Kukova1,2, Lili Chan3, Aparna Saha4, Girish Nadkarni3, Sandra Alfano5, F Perry Wilson1,2, Mark A Perazella1, Chirag R Parikh6. 1. Sections of Nephrology and. 2. Program of Applied Translational Research, Yale School of Medicine, New Haven, Connecticut. 3. Division of Nephrology, Department of Medicine, and. 4. The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, New York; and. 5. General Internal Medicine, and. 6. Division of Nephrology, School of Medicine, Johns Hopkins University, Baltimore, Maryland chirag.parikh@jhmi.edu.
Abstract
BACKGROUND AND OBJECTIVES: Patients are informed of the risk of kidney biopsy-related complications using data from nonhospitalized patients, which may underestimate the risk for hospitalized patients. We evaluated the rate and risk factors of kidney biopsy-related complications in hospitalized patients with acute kidney disease (AKD) to better estimate the risk in this population. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used data from the Yale biopsy cohort to evaluate rates of kidney biopsy-related complications including adjudicated procedure-related bleeding requiring blood transfusions or angiographic interventions, medium- or large-sized hematomas, reimaging after biopsy including abdominal ultrasonography or computed tomography, and death in hospitalized patients with AKD (including AKI). We evaluated univariable and multivariable association of risk factors with transfusions. We compared rates of complications between hospitalized and nonhospitalized patients. RESULTS: Between 2015 and 2017, 159 hospitalized patients underwent a kidney biopsy for AKD evaluation, of which 80 (51%) had stage 1 AKI, 42 (27%) had stage 2 (or higher) AKI, and 27 (17%) had AKD (without AKI). Of these, 12 (8%; 95% confidence interval [95% CI], 5% to 15%) required a transfusion, three (2%; 95% CI, 1% to 5%) required an intervention, 11 (7%; 95% CI, 4% to 12%) had hematoma, and 31 (20%; 95% CI, 14% to 26%) required reimaging after biopsy. Of the four (3%; 95% CI, 1% to 6%) deaths during hospitalization, none were related to the biopsy. Female sex, lower platelet count, and higher BUN were associated with postbiopsy transfusions on univariable and multivariable analyses. Trainee as proceduralist and larger needle gauge were associated with transfusions in univariable, but not multivariable, analysis. Nonhospitalized patients had lower rates of transfusion than hospitalized patients, although the latter also had lower prebiopsy hemoglobin and greater surveillance after biopsy. CONCLUSIONS: Hospitalized patients experience higher risk of postbiopsy complications than previously reported and several factors, such as lower platelet count, female sex, and higher BUN, are associated with this risk.
BACKGROUND AND OBJECTIVES:Patients are informed of the risk of kidney biopsy-related complications using data from nonhospitalized patients, which may underestimate the risk for hospitalized patients. We evaluated the rate and risk factors of kidney biopsy-related complications in hospitalized patients with acute kidney disease (AKD) to better estimate the risk in this population. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used data from the Yale biopsy cohort to evaluate rates of kidney biopsy-related complications including adjudicated procedure-related bleeding requiring blood transfusions or angiographic interventions, medium- or large-sized hematomas, reimaging after biopsy including abdominal ultrasonography or computed tomography, and death in hospitalized patients with AKD (including AKI). We evaluated univariable and multivariable association of risk factors with transfusions. We compared rates of complications between hospitalized and nonhospitalized patients. RESULTS: Between 2015 and 2017, 159 hospitalized patients underwent a kidney biopsy for AKD evaluation, of which 80 (51%) had stage 1 AKI, 42 (27%) had stage 2 (or higher) AKI, and 27 (17%) had AKD (without AKI). Of these, 12 (8%; 95% confidence interval [95% CI], 5% to 15%) required a transfusion, three (2%; 95% CI, 1% to 5%) required an intervention, 11 (7%; 95% CI, 4% to 12%) had hematoma, and 31 (20%; 95% CI, 14% to 26%) required reimaging after biopsy. Of the four (3%; 95% CI, 1% to 6%) deaths during hospitalization, none were related to the biopsy. Female sex, lower platelet count, and higher BUN were associated with postbiopsy transfusions on univariable and multivariable analyses. Trainee as proceduralist and larger needle gauge were associated with transfusions in univariable, but not multivariable, analysis. Nonhospitalized patients had lower rates of transfusion than hospitalized patients, although the latter also had lower prebiopsy hemoglobin and greater surveillance after biopsy. CONCLUSIONS: Hospitalized patients experience higher risk of postbiopsy complications than previously reported and several factors, such as lower platelet count, female sex, and higher BUN, are associated with this risk.
Authors: Richard W Toner; Laura Pizzi; Brian Leas; Samir K Ballas; Alyson Quigley; Neil I Goldfarb Journal: Appl Health Econ Health Policy Date: 2011 Impact factor: 2.561
Authors: Paul M Palevsky; Kathleen D Liu; Patrick D Brophy; Lakhmir S Chawla; Chirag R Parikh; Charuhas V Thakar; Ashita J Tolwani; Sushrut S Waikar; Steven D Weisbord Journal: Am J Kidney Dis Date: 2013-03-15 Impact factor: 8.860
Authors: Abel Torres Muñoz; Rafael Valdez-Ortiz; Carlos González-Parra; Elvy Espinoza-Dávila; Luis E Morales-Buenrostro; Ricardo Correa-Rotter Journal: Arch Med Sci Date: 2011-11-08 Impact factor: 3.318
Authors: Dennis G Moledina; Bettina Cheung; Lidiya Kukova; Randy L Luciano; Aldo J Peixoto; F Perry Wilson; Sandra Alfano; Chirag R Parikh Journal: Kidney Int Rep Date: 2017-11-20
Authors: Kenaz Bakdash; Kristofer M Schramm; Aparna Annam; Matthew Brown; Kimi Kondo; Jonathan D Lindquist Journal: Semin Intervent Radiol Date: 2019-05-22 Impact factor: 1.513
Authors: Emilio D Poggio; Robyn L McClelland; Kristina N Blank; Spencer Hansen; Shweta Bansal; Andrew S Bomback; Pietro A Canetta; Pascale Khairallah; Krzysztof Kiryluk; Stewart H Lecker; Gearoid M McMahon; Paul M Palevsky; Samir Parikh; Sylvia E Rosas; Katherine Tuttle; Miguel A Vazquez; Anitha Vijayan; Brad H Rovin Journal: Clin J Am Soc Nephrol Date: 2020-10-15 Impact factor: 8.237
Authors: Jonathan J Hogan; Jonathan G Owen; Shira J Blady; Salem Almaani; Rupali S Avasare; Shweta Bansal; Oliver Lenz; Randy L Luciano; Samir V Parikh; Michael J Ross; Deep Sharma; Harold Szerlip; Shikha Wadhwani; Raymond R Townsend; Matthew B Palmer; Katalin Susztak; Amy K Mottl Journal: Clin J Am Soc Nephrol Date: 2020-04-27 Impact factor: 8.237
Authors: Dennis G Moledina; F Perry Wilson; Jordan S Pober; Mark A Perazella; Nikhil Singh; Randy L Luciano; Wassim Obeid; Haiqun Lin; Michael Kuperman; Gilbert W Moeckel; Michael Kashgarian; Lloyd G Cantley; Chirag R Parikh Journal: JCI Insight Date: 2019-05-16
Authors: Kathleen D Liu; Stuart L Goldstein; Anitha Vijayan; Chirag R Parikh; Kianoush Kashani; Mark D Okusa; Anupam Agarwal; Jorge Cerdá Journal: Clin J Am Soc Nephrol Date: 2020-04-21 Impact factor: 8.237
Authors: Dennis G Moledina; F Perry Wilson; Lidiya Kukova; Wassim Obeid; Randy Luciano; Michael Kuperman; Gilbert W Moeckel; Michael Kashgarian; Mark A Perazella; Lloyd G Cantley; Chirag R Parikh Journal: Nephrol Dial Transplant Date: 2021-09-27 Impact factor: 5.992